Johnson & Johnson released data from a study showing the effectiveness of a booster shot for its coronavirus vaccine. The company's single-shot vaccine does not have the same efficacy as the two-dose vaccines made by Pfizer and Moderna, but the study shows a second dose brings the efficacy against mild-to-severe COVID up to 94%.
The results of the study have not been published in a peer-reviewed journal, but the drugmaker plans to submit the data to the Food and Drug Administration as it applies for approval for a second booster shot.
"With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson. "We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination."
The pharmaceutical company said that the study also showed that its vaccine continues to provide "strong and robust immune responses that are durable and persistent through eight months."
According to the Centers for Disease Control and Prevention, over 14 million people in the United States have received Johnson & Johnson's single-dose vaccine.